CN1016169B - 制备药用咪唑衍生物的方法 - Google Patents

制备药用咪唑衍生物的方法

Info

Publication number
CN1016169B
CN1016169B CN88101452A CN88101452A CN1016169B CN 1016169 B CN1016169 B CN 1016169B CN 88101452 A CN88101452 A CN 88101452A CN 88101452 A CN88101452 A CN 88101452A CN 1016169 B CN1016169 B CN 1016169B
Authority
CN
China
Prior art keywords
hydroxyl
formula
butyl
amino
tert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CN88101452A
Other languages
English (en)
Chinese (zh)
Other versions
CN88101452A (zh
Inventor
威谦姆·克劳斯
马克·莫他富
瑞纳特·姆瑟
尼克拉斯·西哥威德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN88101452A publication Critical patent/CN88101452A/zh
Publication of CN1016169B publication Critical patent/CN1016169B/zh
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Resins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN88101452A 1987-03-20 1988-03-19 制备药用咪唑衍生物的方法 Expired CN1016169B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH107387 1987-03-20
CH1073/87 1987-03-20

Publications (2)

Publication Number Publication Date
CN88101452A CN88101452A (zh) 1988-10-05
CN1016169B true CN1016169B (zh) 1992-04-08

Family

ID=4201822

Family Applications (1)

Application Number Title Priority Date Filing Date
CN88101452A Expired CN1016169B (zh) 1987-03-20 1988-03-19 制备药用咪唑衍生物的方法

Country Status (23)

Country Link
US (1) US4908363A (OSRAM)
EP (1) EP0283857B1 (OSRAM)
JP (1) JPS63253070A (OSRAM)
KR (1) KR880011117A (OSRAM)
CN (1) CN1016169B (OSRAM)
AT (1) ATE73777T1 (OSRAM)
AU (1) AU613349B2 (OSRAM)
CS (1) CS276093B6 (OSRAM)
DE (1) DE3869163D1 (OSRAM)
DK (1) DK59888A (OSRAM)
ES (1) ES2032482T3 (OSRAM)
FI (1) FI880813A7 (OSRAM)
GR (1) GR3004729T3 (OSRAM)
HU (1) HU201312B (OSRAM)
IL (1) IL85725A (OSRAM)
MC (1) MC1919A1 (OSRAM)
MX (1) MX10721A (OSRAM)
NO (1) NO170215C (OSRAM)
NZ (1) NZ223862A (OSRAM)
PT (1) PT87025B (OSRAM)
SU (1) SU1657057A3 (OSRAM)
YU (1) YU46444B (OSRAM)
ZA (1) ZA881810B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073566A (en) * 1989-11-30 1991-12-17 Eli Lilly And Company Angiotensin ii antagonist 1,3-imidazoles and use thereas
US5401851A (en) * 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US5574057A (en) * 1993-02-03 1996-11-12 University Of Utah Research Foundation Naamidine A extracted from sea sponges and methods for its use as an anti-tumor agent
US5523310A (en) * 1994-12-05 1996-06-04 Hoffmann-La Roche Inc. 1,2,3-triazole derivatives
WO2000031052A1 (en) 1998-11-23 2000-06-02 F. Hoffmann-La Roche Ag Synthesis of anti-inflammatory [1,2,3]triazoles
DE10132896A1 (de) * 2001-07-06 2003-01-16 Bayer Cropscience Ag Heterocyclische Amidderivate
WO2003010143A1 (en) * 2001-07-26 2003-02-06 Samsung Electronics Co., Ltd. Dialkylhydroxybenzoic acid derivatives containing metal chelating groups and their therapeutic uses
US6737433B1 (en) * 2002-12-16 2004-05-18 Laboratoire Theramex 1-N-phenylamino-1H-imidazole derivatives as aromatase inhibitors and pharmaceutical compositions containing them
JP2004196795A (ja) * 2002-12-16 2004-07-15 Wyeth 外部寄生虫駆除剤としてのｎ−フェニル−３−シクロプロピルピラゾール−４−カルボニトリル

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457859A (en) * 1980-07-31 1984-07-03 Ivaschenko Alexandr V Mesomorphic material containing 2,2'-azoimidazole compounds containing 1,1'-benzylideneamino substituents
DE3674054D1 (de) * 1985-04-26 1990-10-18 Hoffmann La Roche 1,3-disubstituierte imidazoliumsalze.
ZW6687A1 (en) * 1986-05-13 1987-12-02 Hoffmann La Roche 1,3-disubstituted imidazolium salts
MW7087A1 (en) * 1986-10-03 1988-05-11 Hoffmann La Roche 1,3-disubstituted imidazolium salts
KR890700582A (ko) * 1987-03-20 1989-04-25 사무엘 에스. 블라이트 살진균성 아미노트리아졸 및 아미노이미다졸

Also Published As

Publication number Publication date
PT87025B (pt) 1992-06-30
HUT49581A (en) 1989-10-30
CN88101452A (zh) 1988-10-05
MX10721A (es) 1993-09-01
DK59888D0 (da) 1988-02-05
MC1919A1 (fr) 1989-04-06
ATE73777T1 (de) 1992-04-15
FI880813A0 (fi) 1988-02-22
JPS63253070A (ja) 1988-10-20
FI880813A7 (fi) 1988-09-21
ES2032482T3 (es) 1993-02-16
CS8800891A2 (en) 1990-09-12
NO881199D0 (no) 1988-03-18
ZA881810B (en) 1988-09-20
IL85725A (en) 1991-12-12
NZ223862A (en) 1990-08-28
NO170215B (no) 1992-06-15
YU46444B (sh) 1993-10-20
NO170215C (no) 1992-09-23
IL85725A0 (en) 1988-08-31
GR3004729T3 (OSRAM) 1993-04-28
CS276093B6 (en) 1992-04-15
HU201312B (en) 1990-10-28
NO881199L (no) 1988-09-21
YU40388A (en) 1990-02-28
PT87025A (pt) 1988-04-01
EP0283857A1 (de) 1988-09-28
DE3869163D1 (de) 1992-04-23
AU1353288A (en) 1988-09-22
AU613349B2 (en) 1991-08-01
KR880011117A (ko) 1988-10-26
DK59888A (da) 1988-09-21
EP0283857B1 (de) 1992-03-18
US4908363A (en) 1990-03-13
SU1657057A3 (ru) 1991-06-15

Similar Documents

Publication Publication Date Title
CN1035616C (zh) 异羟肟酸衍生物
CN1043762C (zh) 用作兴奋性氨基酸受体拮抗剂的化合物及其药物组合物
CN1061654C (zh) 四唑衍生物的制备方法
US5268375A (en) Dinitrogen heterocyclic derivatives N-substituted by a biphenylmethyl group, and the pharmaceutical compositions in which they are present
CN1053190C (zh) 新的喹喔啉二酮衍生物、其制备方法和作为药物的应用
CN1832927A (zh) 新型γ－分泌酶抑制剂
CN87100723A (zh) 醌衍生物，它们的制备和使用
CN1436185A (zh) 凝血酶受体拮抗药
CN1034918A (zh) 化学化合物
CN1473154A (zh) 2,3-二氮杂萘酮衍生物
CN1182425A (zh) 苯并咪唑化合物及其用作gabaa受体复合物调节器的用途
CN1349524A (zh) 血管紧张肽原酶抑制剂
CN1226248A (zh) 用于抑制细胞增殖的取代的双吲哚基马来酰亚胺
CN1209358C (zh) αLβ2介导细胞粘连的抑制剂
CN1016169B (zh) 制备药用咪唑衍生物的方法
EP0433149A2 (fr) Antagonistes de la sérotonine, leur préparation et les médicaments les contenant
CN1067892A (zh) 新的吡咯并[2，3-b]吡啶衍生物的制备方法
HU189747B (en) Process for producing 1-phenyl-2/1h,3h/-indolone derivatives and pharmaceutical compositions containing them
CN1017245B (zh) 咪唑啉酮化合物的制备方法
CN1942437A (zh) 作为环氧化酶－1－环氧化酶－2抑制剂的取代氮杂环丁烷化合物及其制备方法和作为药物的用途
CN86107695A (zh) 不同的氮-取代的3-哌啶羧酸或氮-取代的3-吡啶羧酸及它们的衍生物
MXPA01000549A (es) Compuestos de imidazol y su uso como inhibidores de adenosin desaminasa.
CN1035828A (zh) 苯并间二氧杂环戊烯衍生物及其制备方法
CN87103528A (zh) 1，3-二取代的咪唑盐类
CN1021050C (zh) 丁烯酰胺衍生物的制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C13 Decision
GR02 Examined patent application
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee